Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
This label-first approach matters because packaging can vary
BPC-157 is NOT suitable for individuals with: Active cancer (as it promotes new blood vessel growth)
Patients with known PPARG loss-of-function variants (associated with partial lipodystrophy) should be monitored for atypical fat redistribution during treatment, as lipolytic stimulation in the context of impaired adipogenesis carries theoretical hepatic lipid accumulation risk
For nerve-related issues, it may take a few weeks for noticeable improvement
it is obtained from food in our diet
Understanding these potential side effects is essential for informed decision-making by healthcare providers and patients, as well as for appropriate monitoring and management strategies during treatment
